- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT03000920
Evaluation of the Short Message Service Effectiveness in the Screening Invitation Strategy for Breast Cancer (USIMaPI) (USIMaPI)
Multicenter Randomized Controlled Trial Evaluating the Effectiveness and Cost-effectiveness of the Use of Short Message Service (SMS) in the Screening Invitation Strategy for Breast Cancer.
Each year in France, breast cancer affects about 48,000 women and is the first cause of cancer death in women with 11,900 deaths estimated.
Since 2004, there is a national organized breast cancer screening (OBCS) programme for asymptomatic women aged 50-74 and with a medium-risk. Every two years, the local cancer screening department sends a personalized invitation mail to eligible women to perform a mammogram and a breast clinical examination. One to two reminder mails are sent to women who have not done the screening after an initial invitation. Despite this programme, almost 47% of women in France do not participate to organized breast cancer screening.
The Short Message Service (SMS) is an innovative communication tool in the field of health, immediate, reliable delivery, low cost and ecological. The use of SMS could be an innovative, low-cost, personalized and ecological way to support the OBCS invitation strategy.
The overall objective of this study is to preserve or even better increase participation in organized breast cancer screening while decreasing the associated costs by including SMS in our screening invitation procedure.
Two SMS interventions will be tested which will correspond to different phases of the OBCS invitation procedure. This sequence of interventions leads us to perform three interlinked trials: a trial of superiority for the first phase (intervention 1: sending an SMS a few days before the initial mail invitation), then two non-inferiority trials for the second phase ( two trials=one for each context of phase 1 _ intervention 2: sending an SMS in place of the first postal reminder).
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
Each year in France, breast cancer affects about 48,000 women and is the first cause of cancer death in women with 11,900 deaths estimated.
Since 2004, there is a national organized breast cancer screening (OBCS) programme for asymptomatic women aged 50-74 and with a medium-risk. Every two years, the local cancer screening department sends a personalized invitation mail to eligible women to perform a mammogram and a breast clinical examination. One to two reminder mails are sent to women who have not done the screening after an initial invitation. Despite this programme, almost 47% of women in France do not participate to organized breast cancer screening.
The Short Message Service (SMS) is an innovative communication tool in the field of health, immediate, reliable delivery, low cost and ecological. The use of SMS could be an innovative, low-cost, personalized and ecological way to support the OBCS invitation strategy.
In databases, there is currently about 10 to 15% of the women with a mobile phone number registered in the target population.
This project will be carried out throughout the Region "Centre-Val de Loire" with six local cancer screening departments The overall objective of this study is to preserve or even better increase participation in organized breast cancer screening while decreasing the associated costs by including SMS in our screening invitation procedure.
Two SMS interventions will be tested which will correspond to different phases of the OBCS invitation procedure. This sequence of interventions leads us to perform three interlinked trials: a trial of superiority for the first phase (intervention 1: sending an SMS a few days before the initial mail invitation), then two non-inferiority trials for the second phase (intervention 2: sending an SMS in place of the first postal reminder).
Justification of methodological choices
- st phase: Addition of the intervention "sending an SMS" (and the associated cost) to what is currently done (versus classical intervention). To be of interest, the tested intervention, the sending of an SMS few days before the initial mail invitation, should allow to significantly increase participation in OBCS (here superiority trial).
- nd phase: This phase will involve women who have had or not the phase 1 intervention and who have not yet participated to the OBCS. Since the contexts in phase 1 are different, a trial for each one must be carry out. In this second phase, the conventional intervention (sending reminder mail 1) will be compare to a cheaper one (sending reminder 1 by SMS). The new strategy will prove interesting if it is not inferior in terms of participation to the OBCS. The analysis of this non-inferiority will be carried out for each context of phase 1 (invitation mail alone OR SMS then invitation mail).
The 4 groups of the study are the followings:
- Group 1 (usual procedure): at least an invitation mail and then one or two reminder by mail if necessary.
- Group 2 : Invitation by mail then reminder 1 by SMS if necessary then reminder 2 by mail if necessary
- Group 3 : One SMS a few days before the Invitation by mail and then one or two reminder(s) by mail if necessary
- Group 4 : One SMS a few days before the Invitation by mail then reminder 1 by SMS if necessary then reminder 2 by mail if necessary
Studietype
Inschrijving (Werkelijk)
Fase
- Niet toepasbaar
Contacten en locaties
Studie Locaties
-
-
-
Blois, Frankrijk
- ADOC41
-
Chartres, Frankrijk
- ADOC28
-
Châteauroux, Frankrijk
- CREDEP
-
Tours, Frankrijk, 37044
- CCDC
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- eligible to the organized breast cancer screening
- residing in the region of Centre-Val de Loire (France)
- Phone number registered in data bases of one of the 6 local cancer screening departments of the region of Centre-Val de Loire (France)
Exclusion Criteria:
- none
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Screening
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Geen tussenkomst: 1_Control
Classic screening invitation strategy with at least an invitation mail and then one or two reminder by mail if necessary.
|
|
|
Experimenteel: 2_SMS Reminder 1
Invitation by mail then reminder 1 by SMS if necessary then reminder 2 by mail if necessary
|
If it is necessary for the women to have a reminder 1, the usual mail will be replaced by an SMS.
|
|
Experimenteel: 3_SMS before invitation
One SMS a few days before the Invitation by mail and then one or two reminder(s) by mail if necessary.
|
A couple of days before the invitation letter, an SMS will be sent to announce the arrival of the invitation letter to the mammogram
|
|
Experimenteel: 4_SMS before invitation + SMS Reminder 1
One SMS a few days before the Invitation by mail then reminder 1 by SMS if necessary then reminder 2 by mail if necessary
|
If it is necessary for the women to have a reminder 1, the usual mail will be replaced by an SMS.
A couple of days before the invitation letter, an SMS will be sent to announce the arrival of the invitation letter to the mammogram
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Phase 1: Compare the participation rates in organized breast cancer screening (and the cost by screened woman) in response to a strategy of sending an SMS before the invitation letter (vs sending the invitation letter alone = usual strategy).
Tijdsspanne: Before the sending time of the reminder 1 (letter or SMS) : from 3 months to 8 months after the invitation letter depending to periods of the concerned local cancer screening department
|
For this first phase, the study aims to demonstrate that the addition of the SMS is superior in terms of participation and participation costs.
|
Before the sending time of the reminder 1 (letter or SMS) : from 3 months to 8 months after the invitation letter depending to periods of the concerned local cancer screening department
|
|
Phase 2: Compare participation rates in organized breast cancer screening (and the cost by screened woman) in response to a strategy of replacing the reminder 1 by mail with a reminder 1 by SMS ( reminder 1 mail = usual strategy).
Tijdsspanne: Before the sending time of the reminder 2 : from 3 months to 6 months after the reminder 1 depending to periods of the concerned local cancer screening department
|
For this second phase, the study aims to demonstrate the non-inferiority of the strategy including the SMS in terms of participation and cost-participation according to the two contexts:
|
Before the sending time of the reminder 2 : from 3 months to 6 months after the reminder 1 depending to periods of the concerned local cancer screening department
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Hoofdonderzoeker: ken HAGUENOER, Dr, Centre de coordination des dépistages des cancers, CHRU de Tours
- Hoofdonderzoeker: Somany SENGCHANH, Dr, Centre de coordination des dépistages des cancers, CHRU de Tours
- Hoofdonderzoeker: Julie Boyard, Centre de coordination des dépistages des cancers, CHRU de Tours
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- INCA15-KH/USIMaPI
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Borstkanker
-
Xijing HospitalActief, niet wervendBorstkanker | Borstkanker (Triple Negative Breast Cancer (TNBC))China
-
Shanghai Henlius BiotechNog niet aan het wervenBorstkanker (Triple Negative Breast Cancer (TNBC))China
-
BioNTech SESeventh Framework ProgrammeVoltooidBorstkanker (Triple Negative Breast Cancer (TNBC))Zweden, Duitsland
-
Novartis PharmaceuticalsVoltooidGeavanceerde Triple Negative Breast Cancer (TNBC) met hoge TAM'sFrankrijk, Italië, Oostenrijk, Taiwan, Verenigde Staten, Spanje, Australië, Korea, republiek van, België, Duitsland, Hongkong, Kalkoen
-
Tianjin Medical University Cancer Institute and...Guangxi Medical University; Sun Yat-sen University; Chinese PLA General Hospital; The First Affiliated Hospital of Zhengzhou University en andere medewerkersVoltooidDe klinische toepassingsgids van Conebeam Breast CTChina
-
Sun Yat-sen UniversityNog niet aan het wervenCancer therapie-geïnduceerde trombocytopenie (CTIT)
-
OHSU Knight Cancer InstituteOregon Health and Science UniversityActief, niet wervendPancreas Adenocarcinoom | Fase III Pancreaskanker American Joint Committee on Cancer v8 | Stadium 0 Pancreaskanker American Joint Committee on Cancer v8 | Stadium I alvleesklierkanker American Joint Committee on Cancer v8 | Stadium IV alvleesklierkanker American Joint Committee on Cancer...Verenigde Staten
-
Centre Hospitalier Universitaire, AmiensVoltooidEnt Cancer ScreeningFrankrijk
-
Hitit UniversityErol Olcok Corum Training and Research HospitalVoltooidHysterectomie (MeSH nr: E04.950.300.399) | Had een hysterectomie ondergaan | Had Not Been Diagnosed With Cancer | Na hysterectomieTurkije (Türkiye)
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)VoltooidAdenocarcinoom van de dunne darm | Stadium III Adenocarcinoom van de dunne darm AJCC v8 | Stadium IIIA Adenocarcinoom van de dunne darm AJCC v8 | Stadium IIIB dunne darm adenocarcinoom AJCC v8 | Stadium IV Adenocarcinoom van de dunne darm AJCC v8 | Ampulla van Vater Adenocarcinoom | Stadium III... en andere voorwaardenVerenigde Staten
Klinische onderzoeken op SMS Reminder 1
-
The Hong Kong Polytechnic UniversityWervingHartinfarct | Draagbaar apparaatHongkong
-
The Hong Kong Polytechnic UniversityVoltooid
-
University of MinnesotaBrown University; University of Michigan; Advanced Medical ElectronicsVoltooidDementie | Ziekte van AlzheimerVerenigde Staten
-
Local Health Unit Barcelos/Esposende, Public Health...Instituto de Saude Publica da Universidade do PortoWervingDikke darm- en rectumkankerPortugal
-
Fred Hutchinson Cancer CenterNational Institute on Drug Abuse (NIDA)IngetrokkenTabaksgebruiksstoornis | Sociale angststoornisVerenigde Staten
-
University of St.GallenWervingMobiele applicaties | Herinneringssystemen | Naleving van de patiëntZwitserland
-
Guangzhou Blood CenterVoltooid
-
Temple UniversityNational Institute of Mental Health (NIMH)Nog niet aan het wervenSpanning | Hiv-behandelingscascade | Hiv-zorgverlies tot follow-up
-
University of MichiganUniversidad de Los Andes, Bogota, ColombiaVoltooid
-
University of PittsburghUniversity of PennsylvaniaVoltooidRisico beperkingVerenigde Staten